Tempus AI Inc (TEM) Stock AnalysisTEMTempus AI Inc

Tempus AI, Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. It offers AI-enabled precision medicine solutions to physicians to deliver personalized patient care and, in parallel, facilitates discovery, development and delivery of optimal therapeutics. It provides three product lines: Genomics, Data and artificial intelligence applications (AI). The Genomics product line leverages its laboratories to provide next generation sequencing (NGS) diagnostics, polymerase chain reaction, profiling, molecular genotyping and other anatomic and molecular pathology testing. The data generated in its lab or ingested into its platform is structured and de-identified, prior to commercialization. Its AI Applications is focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools. It operates in the Healthcare sector.

Tempus AI Inc is currently not a good buy due to its recent price decline and negative earnings, despite some positive revenue growth. The current price is $64.72, which is significantly below the analyst price targets ranging from $66 to $95. However, the RSI is at 30.406, indicating that the stock is oversold, which could present a buying opportunity if the fundamentals improve. The main risk is the company's high debt-to-equity ratio of 305.82%, which raises concerns about financial stability.